In honor of March Madness, the Motley Fool's health-care team assembled their own bracket consisting of the 16 largest and best pharmaceutical and biotech stocks on the market. The series kicks off with a tough matchup between two of the biggest players in the diabetes space: Sanofi (NYSE: SNY ) and Eli Lilly (NYSE: LLY ) . To learn the bull and bear cases for each stock -- and to see which stock will move on to the Elite Eight -- watch the following video.
Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.